Cancer vaccine - Norsk Hydro

Drug Profile

Cancer vaccine - Norsk Hydro

Alternative Names: EMD 249590; Ras cancer vaccine - Norsk Hydro; Ras vaccine - Norsk Hydro

Latest Information Update: 03 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Norsk Hydro
  • Class Cancer vaccines
  • Mechanism of Action Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 29 Nov 2000 Merck KGaA has returned all rights to the Ras vaccine to Norsk Hydro
  • 06 Jul 2000 A phase II study in patients with pancreatic cancer has been added to the Cancer therapeutic trials section
  • 07 Jul 1999 Investigation in Colorectal cancer in Europe (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top